Skip to main content
+39 0131 383132
Via Tortrino, 13 15048 Valenza (AL)
info@alfakjn.com

Joyflex Proakjn® XL

Sodium hyaluronate 1.6% (48 mg) + MSM 5% (150 mg) — high-volume syringe

The higher-dose version of the Proakjn patent, in a larger-volume single dose: same mechanism, coverage in a single injection.
CLASS

Class III medical device

FORMAT

3 ml syringe

Dosage

1 injection

Patent

Active

Joyflex Proakjn® XL is the patented medical device that integrates viscosupplementation and prolotherapy in a higher-volume syringe (3 ml), with a higher dosage of hyaluronic acid (48 mg) and MSM (150 mg). The active patent covers the combination of the two therapeutic actions, positioning the product exclusively in the advanced intra-articular market.

It shares with Proakjn the mechanism (native HA + hyperosmolar MSM, anti-inflammatory and regenerative action), in a higher-dosage, single-administration configuration.

  • Dosage: a single injection to cover the course.

  • HA 48 mg/3 ml + MSM 150 mg dosage.

  • Indicated where the Proakjn profile is sought with the advantage of the single-dose.

Evidence
Same evidence base as Proakjn (RCT 1,177 patients, WOMAC scale; bibliography in the Proakjn XL folder).

Specification

Value

Active ingredient

Linear sodium hyaluronate + MSM

Molecular weight

0.8–1.2 million Daltons

Viscosity

70,000–120,000 cP

Concentration

48 mg + 150 mg / 3 ml

Osmolarity

800–900 mOsm/kg

pH

6,5–7,5

Volume

3 ml

Origin

Biofermentation

Dosage

1 injection (6/12 months coverage)

Shelf life

36 months

Specification

Value

Active ingredient

Linear sodium hyaluronate + MSM

Molecular weight

0.8–1.2 million Daltons

Viscosity

70,000–120,000 cP

Concentration

48 mg + 150 mg / 3 ml

Osmolarity

800–900 mOsm/kg

pH

6,5–7,5

Volume

3 ml

Origin

Biofermentation

Dosage

1 injection (6/12 months coverage)

Shelf life

36 months

The core differentiation product, in a higher-dosage and single-dose version. It enables the same premium clinical narrative as Proakjn while adding the single-administration argument — useful in high-volume settings and compliance-sensitive markets.

Reference channel

Advanced intra-articular, premium settings that enhance high-dose single-dose.

Support included

  • Complete technical and clinical documentation, with patent dossier (current European regulations, in English).

  • Presentation materials focused on differentiation from competitors.

  • Support for premium positioning.

  • Willingness to consider local trade names, subject to regulatory compliance.

Compare the line — Joyflex joint references

Highlighting the column of Joyflex Proakjn XL - the product on this page.

Specification
Joyflex 1.6%
Joyflex 2%
Joyflex One
Proakjn
Proakjn XL
Active ingredient
linear HA
linear HA
linear HA
HA + MSM
HA + MSM
Mol. weight (Da)
1.2–1.5m
1.2–1.5m
1.2–1.5m
0.8–1.2m
0.8–1.2m
Viscosity (cP)
70–120k
150–290k
150–290k
70–120k
70–120k
Concentration
32 mg/2 ml
40 mg/2 ml
80 mg/4 ml
32+100 mg/2 ml
48+150 mg/3 ml
Osmolarity
270–330
270–330
270–330
800–900
800–900
pH
6,5–7,5
6,5–7,5
6,5–7,5
6,5–7,5
6,5–7,5
Volume
2 ml
2 ml
4 ml
2 ml
3 ml
Injections
3
3
1
3
1
Patent
-
-
-
Yes
Yes
Shelf life
36 months
36 months
36 months
36 months
36 months

Add this product to your portfolio

I have read the privacy policy I authorise the processing of my personal data in accordance with EU Regulation 2016/679 (GDPR)*

Innovative Made in Italy products in the medical sector for improving patients' quality of life.

**EUDAMED SRN ID**: IT-MF-000009936

CONTACT US

Mon-Fri 8.30-12.30 / 14.00-17.00
Via Carlo Tortrino, 13 — 15048 Valenza (AL)
Piazza della Repubblica, 22 — 27026 Garlasco (PV)